The best-characterized adverse prognostic factor associated with neuroblastoma progression is amplification of the MYCN oncogene, which dysregulates protein kinase C (PKC) leading to constitutive phosphorylation of a number of growth factor receptors, and downregulation of CDH2 affecting cell adhesion [190,191]. This evidence concerns the gene MYCN and neuroblastoma.